ROKIT Healthcare

What ROKIT Healthcare does

ROKIT Healthcare is a Korea-based, KOSDAQ-listed (ticker 376900 since May 2025) AI-driven regenerative medicine company commercializing an integrated Organ Regeneration Platform (ORP) that combines AI wound/affected-area modeling, patient-derived autologous extracellular matrix bio-ink, and medical-grade 3D bioprinting to produce customized regenerative patches in the operating room. Its product stack is anchored by the Dr. INVIVO AI Regen Kit (single-use medical device, Korean approval 제23-9호), the AiD Regen AI scanning app, the Dr. INVIVO 4D2/4D6 bioprinters, and proprietary INVIVO-Gel and Humantein biomaterials, with indication-specific sub-modules for skin regeneration (commercialized, 94.9% success rate in 3-year RWE across 6 countries, 0 amputations), cartilage regeneration (4-year biopsy-confirmed hyaline-like cartilage, FDA EAP pursuit in Q3 2026), kidney regeneration (AI omentum patch with Harvard Medical School 62.5% preclinical regeneration rate, world-first human clinical in July 2026), and veterinary/equine applications. The company also operates three adjacent businesses: ROKIT Genomics (single-cell RNA sequencing services with an AI analysis partnership via Bionexus), a Korean MFDS-approved Human Tissue Bank distributing 10 allograft categories, and ROKIT America (premium reverse-aging NMN/senolytic supplements via direct-to-consumer channels, with a Nasdaq Global Market listing pending).

The business model blends multiple monetization streams: unit-priced hardware sales (AI Regen Kits, bioprinters), consumable bio-ink revenue (INVIVO-Gel, Humantein), fee-for-service genomics and tissue bank distribution, AI algorithm licensing royalties (18% with 20/20 BioLabs in the US, 20% with LifeHope in Saudi Arabia, both for the AI Kidney CKD prediction tool), and equity-structured geographic expansion (the $20.7M USD ROKIT MENA joint venture with UAE's Master Investment Group). Go-to-market is multi-modal: direct enterprise field sales to hospitals and medical institutions in Korea, licensing/royalty/OEM partnerships for international expansion (20/20 BioLabs US, LifeHope/Albayat Saudi, Master Investment Group UAE, Tights Medical US diabetic foot, Kakao Healthcare Korea diabetes prevention, Northwell Health US skin cancer, University of Perugia EU equine), and direct-to-consumer e-commerce for the reverse-aging line. As of 2025, the company had sales contracts in 46 countries, an export ratio of 43.9% of revenue, 5,350 cumulative AI Regen Kits sold, and a 2025 consolidated revenue of 26,247 million KRW (~$19M USD), with the first operating profit recorded in 2025.

Name

ROKIT Healthcare

Legal name

주식회사 로킷헬스케어 (ROKIT HEALTHCARE Inc.)

Website

https://rokithealthcare.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

ROKIT Healthcare (KOSDAQ 376900) is a Korea-based AI-driven regenerative medicine company commercializing an integrated 3D bioprinting platform that produces patient-autologous organ regeneration patches for skin, cartilage, and kidney indications, serving hospitals, longevity testing labs, and consumers across 46 countries.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

akta.pro secondary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• 3D bioprinting platform
• Regenerative medicine devices
• AI wound modeling
• Autologous tissue regeneration
• Bioink manufacturing

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices8 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Dr. INVIVO AI Regen KIT Sales (Medical Device): Unit sales of single-use medical device kits (제허 23-9호) to hospitals and clinics for patient-specific regenerative procedures. 2025 global KIT estimated sales volume 7,340 units (~3.2x growth from 2,276 units in 2024). Cumulative kits sold to 2025: 5,350 units.
2. AI Kidney Algorithm Licensing (Royalty): Licensing of AI-based chronic kidney disease (CKD) prediction algorithm with 18% royalty rate to 20/20 BioLabs in the US (US launch planned April 2026; ~$33 per user), and 20% royalty in Saudi Arabia with LifeHope/Albayat Medical (~$100 per test). Includes ROKIT reimbursement of 1/3 of sales/marketing expenses.
3. ROKIT MENA Joint Venture (Equity + Tech): Equity investment of approximately $20.7M USD (~30 billion KRW) from UAE Master Investment Group to establish ROKIT MENA; ROKIT Healthcare contributes AI organ regeneration platform technology as in-kind investment. JV to operate regenerative medicine clinics in UAE targeting GCC and European markets.
4. Reverse Aging Supplements (ROKIT America): Direct-to-consumer sales of premium NMN and reverse-aging nutraceuticals (NMN Pterostilbene, NMN Long-Lasting, Fisetin, Spermidine, NR Glutathione) via ROKIT America's own online storefront (Naver Smart Store, Global Shop).
5. Human Tissue Bank Distribution (10 tissue types): MFDS-approved distribution of human tissue grafts (bone, cartilage, tendon, skin, amnion, ligament, fascia, nerve, blood vessel, pericardium) to medical institutions. Established 2018 as a dedicated subsidiary tissue bank.
6. Genomics Single-Cell Analysis Services (ROKIT Genomics): Fee-for-service single cell RNA sequencing, NGS sequencing, and bespoke data analysis services for research institutions and government agencies. Full-service pipeline from research consulting to data interpretation.
7. Bio-ink and Biomaterial Sales (INVIVO-Gel, Humantein): Recurring revenue from sales of proprietary bio-inks and biomaterials (INVIVO-Gel, Humantein) to research institutions and 3D bioprinter users as consumables.
8. Equipment Sales (Dr. INVIVO 4D2 / 4D6 Bioprinters): Capital equipment sales of medical-grade 3D bioprinters (Dr. INVIVO 4D2 Upgrade, 4D2 Premium, 4D6) to research institutions and hospitals.

Pricing tiers

Go-to-market motion5 records

Marketing channels9 records

Core offering

ROKIT Healthcare develops and sells an AI-driven hyper-personalized Organ Regeneration Platform (ORP) that combines a single-use adipose-tissue processing medical device (Dr. INVIVO AI Regen Kit), an AI wound-scanning app (AiD Regen), medical-grade 3D bioprinters (Dr. INVIVO 4D2/4D6), and proprietary bio-inks (INVIVO-Gel, Humantein) to produce patient-specific autologous regenerative patches at the point of care. The platform underpins indication modules for skin, cartilage, and kidney regeneration, and is sold alongside reverse-aging consumer supplements (ROKIT America), single-cell genomics services (ROKIT Genomics), and an MFDS-approved human tissue bank.

Product overview

ROKIT Healthcare is a Korean KOSDAQ-listed AI-driven regenerative medicine platform company offering a portfolio organized around a core AI Organ Regeneration Platform (ORP) plus multiple indication sub-modules and complementary business lines. The ORP combines four integrated components (Dr. INVIVO AI Regen KIT for autologous fat separation, the AiD Regen AI scanning app, the medical Dr. INVIVO 3D bioprinter, and patient-derived regeneration-niche bioink) to deliver Just-In-Time personalized regeneration in the operating room. Indication sub-modules built on the ORP include Skin Regeneration (commercialized, CE MDR / FDA registered, 94.9% success in 3-year global RWE), Cartilage Regeneration (clinical-stage with 4-year biopsy data and FDA EAP pursuit), Kidney Regeneration via the AI omentum patch (Harvard-validated, world-first human clinical in July 2026), and a Pet Organ Regeneration module extending into veterinary (including European racehorse regeneration). Alongside the ORP, ROKIT operates the ROKIT Genomics subsidiary for single-cell RNA sequencing services (with AI-based analysis under a Bionexus MOU), a Tissue Bank distributing 10 categories of MFDS-approved human tissue allografts, and the ROKIT America subsidiary's Reverse Aging Solution line of NMN- and senolytic-based nutraceuticals. Supporting the platform are the research-grade Dr. INVIVO 4D2 / 4D6 3D bioprinters and INVIVO-Gel and Humantein biomaterials. Standalone AI products include the proprietary AI Kidney CKD prediction algorithm (licensed in the US and Saudi Arabia).

Differentiator

Problem solved

Functional benefit

Brands

• Dr. INVIVO: ROKIT's proprietary medical 3D bioprinter product line, including Dr. INVIVO AI Regen KIT (일회용 의료기기, 품목허가 제허 23-9호), Dr. INVIVO 4D2, and Dr. INVIVO 4D6 for use in the Organ Regeneration Platform.
• AiD Regen
• INVIVO-Gel
• Humantein
• ROKIT America
• ROKIT Genomics (로킷제노믹스)

Products and services

• Organ Regeneration Platform (ORP) AI-driven personalized organ regeneration platform that combines AI wound/affected-area automatic modeling, 3D bioprinting, and patient ECM-based regeneration-niche bioink to produce customized tissues in the operating room for treatment of intractable chronic diseases (skin, cartilage, kidney, veterinary). For hospitals, clinics, and research institutions.
• Dr. INVIVO AI Regen Kit Single-use disposable medical device (제증 23-9호) for separating and processing autologous adipose tissue harvested from the patient for re-injection; the first step of the ORP workflow for regenerative bioink preparation. Sold to hospitals and clinics.
• AiD Regen (AI Wound Scanning App) AI-driven wound/affected-area scanning application that captures precise wound geometry and generates digital files for downstream 3D bioprinting of customized regenerative patches; part of the ORP workflow for medical institutions.
• Dr. INVIVO Medical 3D Bioprinter Medical-grade 3D bioprinter that prints patient-customized regeneration-niche patches using regenerative bioink derived from autologous tissue; designed for use directly in surgical settings. Sold to hospitals and surgical centers.
• Skin Regeneration Platform Commercialized ORP indication module for diabetic foot ulcer (DFU) and other chronic skin wound treatment; CE MDR and FDA medical device registered; reports 94.9% regeneration success in 3-year global RWE across 6 countries with 0 amputations. Targets diabetic foot, burns, scars, pressure ulcers, and skin cancer.
• Cartilage Regeneration Platform ORP indication module for osteoarthritis cartilage regeneration in clinical development; 4-year long-term biopsy data confirms true hyaline-like cartilage regeneration; pursuing US FDA Expanded Access Program (EAP) for rare intractable cartilage diseases.
• Kidney Regeneration Platform (AI Omentum) ORP indication module targeting chronic kidney disease (CKD) and renal failure; AI omentum-based autologous patch validated by Harvard Medical School (62.5% kidney function regeneration in preclinical); world's first human clinical surgery scheduled for July 2026; targets the ~700M-800M global CKD patient population.
• Pet Organ Regeneration Platform Veterinary ORP application derived from prior domestic pet clinical cases; international clinical expansion underway including European racehorse cartilage/skin regeneration in collaboration with University of Perugia.
• AI Kidney (CKD Prediction Algorithm) Proprietary AI-powered chronic kidney disease prediction algorithm licensed internationally (US: 20/20 BioLabs at 18% royalty; Saudi Arabia: LifeHope at 20% royalty); designed to be integrated into longevity testing platforms and the AI Kidney Regeneration Platform; targets ~700M global CKD patients.
• Reverse Aging Solution (ROKIT America) ROKIT America's premium reverse-aging nutraceutical line built on 99.9% ultra-purity NMN (NAD+ precursor) and senolytic/antioxidant ingredients; manufactured in US FDA cGMP-approved facilities with patented NutraJIT absorption technology delivering 7x bioavailability. Sold direct-to-consumer.
• ROKIT Genomics Single-Cell RNA Sequencing Solution Subsidiary offering a one-stop total service for single-cell transcriptomics (scRNA-seq): research consulting, library preparation, NGS sequencing, and bespoke data analysis with real-time sample tracking; targets national institutions and research clients in oncology, immunology, stem cell, and organoid research.
• Tissue Bank (Human Tissue Bank) MFDS-approved Human Tissue Bank (established 2018) distributing 10 types of human tissue allografts (bone, cartilage, tendon, skin, amnion, ligament, fascia, nerve, blood vessel, pericardium) to medical institutions; plans expansion into processed-tissue banking.
• Dr. INVIVO 4D2 / 4D6 Research 3D Bioprinters Next-generation 3D bioprinting research systems with multi-print-head configurations and precise temperature/pressure/extrusion control for fabricating complex tissue structures in wound healing, cancer modeling, bone regeneration, and other research applications; sold to research institutions.
• INVIVO-Gel (Bioink) Gelatin-based methacryloyl-modified bioink offering excellent photopolymerization capability, high structural stability, biocompatibility, and cell adhesion/proliferation support for 3D bioprinting research; sold as consumable to research institutions.
• Humantein (Bio Material) Human-cell-derived whole extracellular matrix (ECM) bioink composed of 300+ proteins and associated cytokines; suitable as an ideal coating material with versatile research applications; sold to research institutions.

Quantifiable outcome

• 94.9% skin regeneration success rate (3-year RWE)
• +12 more outcomes

Named customers13 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature10 records

Scale indicators22 records

Recent moves13 records

Expansion highlights8 records

Direct peers

• Elysium Health: Premium consumer longevity and cellular health supplement company (Basis/NR and related NAD+-boosting products). Direct comparable to ROKIT America's reverse-aging NMN/senolytic DTC product line, with similar premium positioning and US e-commerce channel mix.
• Vericel: US commercial-stage regenerative medicine company (MACI autologous cartilage repair). The most relevant commercial-stage comparable for ROKIT's cartilage regeneration platform, sharing the autologous cell-based cartilage indication and US regulatory pathway.
• Renalytix AI: AI-enabled clinical diagnostics company commercializing KidneyIntelX for chronic kidney disease risk prediction. Direct comparable to ROKIT's AI Kidney CKD prediction algorithm, with similar US go-to-market via clinical channels and recurring per-test economics.
• BICO (formerly CELLINK): Global leader in 3D bioprinters, bio-inks (including gelatin-based methacryloyl products comparable to ROKIT's INVIVO-Gel), and regenerative medicine workflow solutions. Direct competitor in bioprinter hardware and bio-ink consumables sold to research institutions.
• Organovo: Pioneer in 3D bioprinting of human tissues for therapeutic and research use. Closest direct comparable to ROKIT's Dr. INVIVO bioprinters and organ regeneration platform, though focused on liver tissue rather than skin/cartilage/kidney indications.
• Allevi (a 3D Systems company): Acquired by 3D Systems, Allevi makes benchtop 3D bioprinters and bio-inks for research customers. Competes with ROKIT's research-grade Dr. INVIVO 4D2/4D6 bioprinters and INVIVO-Gel/Humantein consumables in the academic and translational research market.

Broad incumbents

• 10x Genomics: Dominant supplier of single-cell RNA sequencing instruments and consumables. Comparable to ROKIT Genomics' scRNA-seq service business on the technology stack and target customer base (research institutions), though ROKIT is a fee-for-service provider rather than an instrument vendor.
• Mesoblast: Late-stage cellular medicines company with FDA-approved products and pipeline across inflammatory and cardiovascular indications. Comparable as a publicly-traded regenerative medicine incumbent pursuing biologic regulatory approvals at scale.

Emerging players

• Pluristem Therapeutics: Cell therapy company developing placenta-derived cell products for multiple indications including muscle injury and wound healing. Overlaps with ROKIT on regenerative wound care and orthobiologics, with comparable clinical-stage profile.
• Aspect Biosystems: Canada-based biotech developing 3D bioprinted tissue therapeutics with a microfluidic bioprinting platform. Overlaps with ROKIT on indication-specific tissue therapeutics and bioprinter R&D, though focused on metabolic disease and immuno-oncology rather than skin/cartilage/kidney.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/ROKIT_GBD
• Facebookfacebook.com/rokithealthcare

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries3 records

Funding overview

Funding rounds6 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ROKIT Healthcare